Last reviewed · How we verify
Ciprofloxacin reference tablet
At a glance
| Generic name | Ciprofloxacin reference tablet |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study of Ciprofloxacin in Healthy Adult Subjects Under Fasting Condition (PHASE1)
- Impact of Formulation on Ciprofloxacin Oral Absorption (PHASE1)
- Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprofloxacin reference tablet CI brief — competitive landscape report
- Ciprofloxacin reference tablet updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI